Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage.

Treatment with SGLT2 inhibitors appears to reduce arterial stiffness. Accordingly, these agents might improve cardiovascular outcomes not only in patients with T2DM and established cardiorenal disease but also in lower-risk patients.